Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults.
about
Immunization of children with secondary immunodeficiencyInfluenza vaccination in HIV-positive subjects: latest evidence and future perspectiveImmunogenicity of a 2009 pandemic influenza virus A H1N1 vaccine, administered simultaneously with the seasonal influenza vaccine, in children receiving chemotherapy.Influenza immunology evaluation and correlates of protection: a focus on vaccines.Safety and immunogenicity of 2009 pH1N1 vaccination in HIV-infected pregnant women.Does vaccine dose predict response to the monovalent pandemic H1N1 influenza a vaccine in children with acute lymphoblastic leukemia? A single-centre study.Neutropenia Precautions for Children Receiving Chemotherapy or Stem Cell Transplantation for Cancer.Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future.Immunization of children receiving immunosuppressive therapy for cancer or hematopoietic stem cell transplantation.Protecting pediatric oncology patients from influenzaImmunogenicity and safety of high-dose trivalent inactivated influenza vaccine compared to standard-dose vaccine in children and young adults with cancer or HIV infectionImmune reconstitution and vaccination outcome in HIV-1 infected children: present knowledge and future directions.Alteration of lymphocyte phenotype and function in sickle cell anemia: Implications for vaccine responses.Serologic response and clinical efficacy of influenza vaccination in children and young adults on chemotherapy for cancer.Serological response to trivalent inactivated influenza vaccine in HIV-infected adults in Singapore.The Effectiveness of Trivalent Inactivated Influenza Vaccine in Children with Acute Leukemia.
P2860
Q26801474-5717EFFC-6131-42CE-8973-9EE16649F047Q27007483-995D5147-38F4-4A99-AAE7-8B1D8BF8C92FQ30357587-A24CF498-7AA6-43EB-B69D-30F7D76EB7ACQ30385397-85A0CACE-B5DF-40FA-8AAA-E879E34E139BQ30426754-7C87D8F1-6470-4D1E-9DF2-F3869AA5E499Q30430658-319F58B2-A27E-49A5-B233-CE01BBF865D3Q35188126-369300F7-DDE2-436C-8F2F-A0AF01BFC898Q35826733-561B9B4E-2461-4D49-B74A-793FBC014F4CQ36250895-08B6A541-3282-4B90-9B33-7AC9783E29B8Q36630470-E9643F53-D1C1-4A65-AADD-56F74F748524Q36984193-36AC7C05-E245-4C5D-B48D-203589586C94Q38036063-CA943160-8608-4A39-AE2A-47412428BE10Q38847491-8CF1F555-B72E-48D9-BFD7-F6D7E0223F4DQ40100431-034139F1-87B6-494F-86C1-A9620696437CQ40300395-606D3358-5198-40D3-98E2-74473A44B5F4Q47700569-E1D0E9A4-4DEE-4347-BB9D-AC04BE668663
P2860
Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults.
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Immunogenicity and safety of i ...... sed children and young adults.
@ast
Immunogenicity and safety of i ...... sed children and young adults.
@en
type
label
Immunogenicity and safety of i ...... sed children and young adults.
@ast
Immunogenicity and safety of i ...... sed children and young adults.
@en
prefLabel
Immunogenicity and safety of i ...... sed children and young adults.
@ast
Immunogenicity and safety of i ...... sed children and young adults.
@en
P2093
P1433
P1476
Immunogenicity and safety of i ...... sed children and young adults.
@en
P2093
Hana Hakim
Kim J Allison
Lee-Ann Van De Velde
Patricia M Flynn
P304
P356
10.1016/J.VACCINE.2011.11.105
P407
P577
2011-12-09T00:00:00Z